https://doi.org/10.55788/004ff717
Dr Antonios Danelakis and colleagues (Norwegian University of Science and Technology, Norway) investigated the predictive value of machine-learning algorithms in diagnosing migraine [1]. They used data from the 2nd and 3rd Nord-Trøndelag Health Study (HUNT), including genotype (genetic dosages of migraine-related risk variants), clinical data, and headache phenotype in 43,197 individuals. General clinical data from the HUNT study included demographics, socioeconomic data, comorbidity, blood pressure, physical characteristics, stimulant/medication use, and non-headache complaints.
The study population included data from 10,286 individuals with headache (24% of the overall population) and 32,911 (76%) individuals as control; 90% of the initial study population was used to train the model, while the remaining 10% was used for testing. In total, 3 datasets were employed: a dataset containing only genotype data (7,840 genetic variants), a dataset containing only clinical data (74 variables), and a combined dataset containing both.
Of all the models in the study, the Light Gradient Boosting Machine (LGBM) model showed the top performance for all datasets. In the genotype dataset, the LGBM model led to an area under the curve (AUC) of 65% in the training population and 63% in the testing population, while in the clinical dataset, the AUC values were 80% and 79%, respectively. In the combined genotype and clinical dataset, the LGBM model led to an AUC of 81% when using the training data and an AUC of 80% for the testing dataset. These numbers are “a good indication of the generalisability of this model,” said Dr Danelakis.
In summary, “migraine could be predicted by machine learning surprisingly well if we consider that none of the typical information that is used for migraine diagnosis was included here,” said Dr Danelakis. However, he added that “predicting migraine based on clinical data provides better results than just using individual genotype data, but the latter still adds some additional information.”
- Danelakis A, et al. Machine learning can predict migraine from genotype and non-headache clinical data with high accuracy. 18th European Headache Congress, 4–7 December 2024, Rotterdam, the Netherlands.
Copyright ©2024 Medicom Medical Publishers
Posted on
Previous Article
« New tool adequately captures multiple pain types in trigeminal neuralgia Next Article
Central arterial stiffness is involved in the pathophysiology of reversible cerebral vasoconstriction syndrome »
« New tool adequately captures multiple pain types in trigeminal neuralgia Next Article
Central arterial stiffness is involved in the pathophysiology of reversible cerebral vasoconstriction syndrome »
Table of Contents: EHC 2024
Featured articles
More education on migraine features is needed
CGRP antagonists show different potencies for CGRP isoforms in different vascular compartments
Understanding Migraine Mechanisms
The locus coeruleus is involved in processing pain in migraine
Cortical spreading depolarisation impacts glymphatic flow, with consequences for migraine aura
Central arterial stiffness is involved in the pathophysiology of reversible cerebral vasoconstriction syndrome
Diagnostic and Predictive Tools
AI can enhance migraine diagnosis using easy-to-measure clinical data
New tool adequately captures multiple pain types in trigeminal neuralgia
MRI analyses suggest that migraine is not associated with altered brain white matter
More education on migraine features is needed
Treatment Innovations
PACAP-targeting therapies: a future option for migraine?
Rapid complete responses with atogepant
Cabergoline is a potential add-on treatment option in patients with migraine
Nitroglycerin-induced migraine targetable by different agents
Rimegepant reduces migraine symptoms through 1 year of treatment
Fremanezumab is a treatment option for paediatric patients with episodic migraine
What brain changes are associated with fremanezumab treatment success?
Preventative Therapies in Real-world Context
Low discontinuation rates with preventative galcanezumab in a real-world setting
Side effects are the main culprit for treatment discontinuation in indomethacin-sensitive headache disorders
Biofeedback training can reduce affected days in episodic migraine
Virtual reality interventions can reduce pain perception of chronic headache
Risk Factors and Long-term Management
Can predisposing factors be targeted to reduce new migraine incidence?
Active migraine comes at a high cost in Spain
Many patients, including non-responders, prefer triptans over non-headache-specific medication
Systemic Conditions and Migraine
DPP-4 is better target to lower migraine rates in patients with type 2 diabetes
CGRP antagonists show different potencies for CGRP isoforms in different vascular compartments
Related Articles
October 27, 2020
Improvement of migraine using CGRP mAbs in a real-world setting
March 15, 2019
Central and peripheral mechanisms in migraine
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com
